항비만 치료제 시장 : 약제 클래스별, 작용기전, 투여 경로, 적응증, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Anti-Obesity Therapeutics Market is projected to grow by USD 21.21 billion at a CAGR of 8.87% by 2032.

The anti-obesity therapeutics market is moving from adjunct lifestyle support to evidence-based chronic disease management. World Health Organization data show that adult obesity has more than doubled since 1990, with more than 1 billion people living with obesity globally in 2022, including 890 million adults and 159 million children and adolescents.

Commercial and clinical momentum is being driven by GLP-1 receptor agonists, dual GIP/GLP-1 agonists, cardiometabolic outcome evidence, and payer reassessment of obesity as a long-term medical condition. Clinical data from STEP and SURMOUNT trials, including weight reductions approaching 15% with semaglutide 2.4 mg and more than 20% with tirzepatide in selected trial populations, have reset expectations for obesity pharmacotherapy and intensified focus on durable outcomes, tolerability, and patient persistence.

Transformative Shifts in the Obesity Treatment Landscape

The landscape is being transformed by the shift from short-duration weight-loss products to chronic metabolic therapies that address obesity-related complications. Regulatory approvals of advanced incretin-based obesity medicines, along with expanding real-world use, have accelerated physician adoption, patient demand, and manufacturing scale-up across injectable obesity drugs.

A second major shift is the convergence of obesity care with cardiovascular, renal, hepatic, sleep, and diabetes management. The SELECT trial reported a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease, strengthening the value proposition for payers and health systems. This evidence is pushing anti-obesity therapeutics beyond cosmetic weight reduction toward measurable cardiometabolic risk reduction.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing anti-obesity therapeutics across discovery, clinical development, commercialization, and patient support. AI-enabled molecular modeling, phenotyping, trial recruitment analytics, and safety signal detection are helping accelerate pipeline decisions for incretin-based drugs, oral peptides, amylin analogs, gut hormone combinations, and next-generation metabolic therapies.

In clinical practice, AI can support obesity risk stratification, adherence prediction, dose-titration workflows, and integrated monitoring of cardiometabolic markers such as glycemic control, blood pressure, lipid levels, and liver health indicators. The strongest near-term impact is expected in identifying patients likely to benefit, improving persistence, and supporting evidence generation from real-world data while maintaining privacy protection, bias control, explainability, and regulatory-grade validation.

Key Regional Insights

North America remains the most commercially advanced region due to high obesity prevalence, strong specialist networks, mature reimbursement infrastructure, and rapid uptake of GLP-1-based obesity pharmacotherapy. Europe is expanding through centralized regulatory pathways, national health technology assessments, and increasing recognition of obesity as a chronic disease, although access varies by country and budget impact concerns remain significant. Asia-Pacific is emerging as a major strategic region as China, India, Japan, South Korea, and Australia confront rising metabolic disease burdens, urban lifestyle changes, and expanding private healthcare demand.

Latin America shows meaningful medical need, led by Mexico and Brazil, where obesity and type 2 diabetes are major public health priorities and nutrition-related chronic disease policies are increasingly prominent. The Middle East, especially GCC markets, is adopting premium metabolic therapies amid high diabetes prevalence, advanced private care infrastructure, and growing interest in preventive cardiometabolic medicine. Africa remains earlier-stage for anti-obesity therapeutics, with access constrained by affordability, diagnostic gaps, medicine availability, and health system capacity, even as urbanization and noncommunicable disease burdens increase across the region.

Key Group Insights

The G7 represents the strongest clinical and commercial base for anti-obesity therapeutics because of advanced regulatory systems, specialist prescribing capacity, established pharmaceutical reimbursement channels, and high levels of cardiometabolic disease diagnosis. The European Union is pivotal for market access strategy, as pricing, reimbursement, and health technology assessment decisions influence uptake across member states and shape evidence requirements for long-term obesity pharmacotherapy, including durability, safety, comorbidity reduction, and budget impact management.

BRICS markets are strategically important because they combine large populations, rising obesity prevalence, expanding middle-class demand, and growing local manufacturing capabilities. ASEAN offers a developing opportunity through urbanization, diabetes prevention priorities, and increasing investment in private healthcare systems, while the GCC is characterized by high cardiometabolic disease burden, premium care adoption, and strong demand for advanced metabolic interventions. NATO is not a healthcare market bloc, but its member economies include many high-income systems where supply security, medicine resilience, regulatory coordination, and advanced clinical infrastructure influence therapeutic availability and continuity of care.

Key Country Insights

The United States is the global demand center for anti-obesity therapeutics, supported by regulatory approvals, broad prescriber awareness, employer health benefits, and high obesity prevalence; CDC data reported U.S. adult obesity prevalence at 40.3% during August 2021 to August 2023. Canada is progressing through public and private reimbursement debates and structured health technology evaluation, while Mexico and Brazil face substantial public health need linked to obesity, type 2 diabetes, cardiovascular disease risk, and changing dietary patterns.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are balancing strong clinical demand against budget impact, with Germany and the United Kingdom serving as influential evidence and access markets because of structured assessment processes and specialist clinical networks. France, Italy, and Spain continue to emphasize reimbursement discipline, prescriber guidance, and long-term value demonstration, while Russia remains shaped by local regulatory requirements, affordability considerations, and supply-chain factors.

China and India represent large-scale growth opportunities due to rising obesity rates, expanding diabetes burdens, and increasing investment in metabolic care, although affordability and broad access remain important constraints. Japan and South Korea emphasize metabolic risk management, aging-population health priorities, and clinical evidence standards, supporting measured adoption of obesity pharmacotherapy. Australia combines high disease awareness with structured reimbursement evaluation and established obesity, diabetes, and cardiovascular care pathways, making evidence quality and cost-effectiveness central to access decisions.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical evidence beyond weight loss, including cardiovascular outcomes, diabetes prevention, obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease, renal markers, mobility, and quality-of-life improvements. Payers increasingly require proof of durable benefit, adherence support, appropriate patient selection, and reduced obesity-related complications to justify broader coverage.

Companies should also invest in scalable manufacturing, cold-chain resilience, oral and longer-acting formulations, pharmacovigilance systems, equitable pricing models, and real-world evidence programs. Partnerships with primary care networks, endocrinologists, cardiologists, hepatologists, sleep specialists, digital health providers, and employers can improve diagnosis, treatment persistence, and outcomes in the anti-obesity therapeutics market. Responsible communication, patient education, and continuity-of-care models will be critical to maintaining trust as demand expands.

Research Methodology

This executive summary is based on verified public health, regulatory, and clinical evidence from sources such as the World Health Organization, U.S. Centers for Disease Control and Prevention, U.S. Food and Drug Administration, European Medicines Agency, national health authorities, and peer-reviewed clinical trial publications. Key evidence includes obesity prevalence trends, regulatory approvals, clinical efficacy data, safety findings, cardiometabolic outcomes, and health system access considerations.

The methodology combines secondary research, cross-validation of clinical and regulatory milestones, assessment of regional healthcare structures, and analysis of market access dynamics. Insights are synthesized to reflect current conditions in anti-obesity therapeutics, including GLP-1 receptor agonists, dual incretin agonists, emerging oral therapies, amylin-based approaches, and next-generation metabolic drug pipelines, while avoiding market sizing, market share, and forecasting claims.

Conclusion

Anti-obesity therapeutics are entering a pivotal phase as clinical efficacy, cardiometabolic outcome data, and patient demand converge. The sector is no longer defined only by weight reduction; it is increasingly linked to cardiovascular risk reduction, diabetes management, liver and sleep-related comorbidity care, health system efficiency, and long-term chronic disease management.

Sustained leadership will depend on evidence quality, manufacturing reliability, affordability, equitable access, safety monitoring, and the ability to integrate pharmacotherapy with digital care, nutrition, physical activity, and behavioral support. Organizations that demonstrate durable health outcomes, responsible commercialization, and patient-centered access are best positioned to shape the next decade of obesity treatment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Anti-Obesity Therapeutics Market, by Drug Class

• 7.1. Prescription Drugs
  • 7.1.1. GLP 1 Receptor Agonists
    • 7.1.1.1. Semaglutide
    • 7.1.1.2. Liraglutide
    • 7.1.1.3. Tirzepatide
  • 7.1.2. Combination Therapies
    • 7.1.2.1. Phentermine Topiramate
    • 7.1.2.2. Bupropion Naltrexone
  • 7.1.3. Lipase Inhibitors
  • 7.1.4. Sympathomimetic Agents
• 7.2. Over the Counter Drugs

8. Anti-Obesity Therapeutics Market, by Mechanism of Action

• 8.1. Centrally Acting Drugs
  • 8.1.1. Appetite Suppressants
  • 8.1.2. Neurotransmitter Modulators
• 8.2. Peripherally Acting Drugs
  • 8.2.1. Fat Absorption Blockers
  • 8.2.2. Metabolic Enhancers
• 8.3. Hormonal Based Therapies

9. Anti-Obesity Therapeutics Market, by Route Of Administration

• 9.1. Oral
  • 9.1.1. Capsules
  • 9.1.2. Tablets
• 9.2. Injectable
  • 9.2.1. Intramuscular
  • 9.2.2. Subcutaneous
• 9.3. Transdermal

10. Anti-Obesity Therapeutics Market, by Indication

• 10.1. Obesity
• 10.2. Overweight with Comorbidities
  • 10.2.1. Type 2 Diabetes
  • 10.2.2. Cardiovascular Diseases
  • 10.2.3. Hypertension
  • 10.2.4. Dyslipidemia
• 10.3. Genetic Obesity Disorders
• 10.4. Hypothalamic Obesity

11. Anti-Obesity Therapeutics Market, by End User

• 11.1. Hospitals
• 11.2. Specialty Clinics
• 11.3. Weight Loss Centers
• 11.4. Homecare Settings
• 11.5. Ambulatory Surgical Centers

12. Anti-Obesity Therapeutics Market, by Distribution Channel

• 12.1. Offline
• 12.2. Online

13. Anti-Obesity Therapeutics Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Anti-Obesity Therapeutics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Anti-Obesity Therapeutics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Aardvark Therapeutics
• 17.2. Altimmune, Inc.
• 17.3. Amgen Inc.
• 17.4. Antag Therapeutics ApS
• 17.5. Ascletis Pharma Inc.
• 17.6. AstraZeneca PLC
• 17.7. Boehringer Ingelheim International GmbH
• 17.8. Currax Pharmaceuticals LLC
• 17.9. Eli Lilly and Company
• 17.10. Hanmi Pharm. Co., Ltd.
• 17.11. Innovent Biologics, Inc.
• 17.12. Kailera Therapeutics
• 17.13. Metsera, Inc.
• 17.14. Novo Nordisk A/S
• 17.15. Pfizer Inc.
• 17.16. Rhythm Pharmaceuticals, Inc.
• 17.17. Roche Holding AG
• 17.18. Sciwind Biosciences
• 17.19. Structure Therapeutics Inc.
• 17.20. Sun Pharmaceutical Industries Ltd.
• 17.21. Takeda Pharmaceutical Company Limited
• 17.22. Teva Pharmaceutical Industries Ltd.
• 17.23. Viking Therapeutics, Inc.
• 17.24. Zealand Pharma A/S
• 17.25. Zydus Lifesciences Limited